Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBR-012 in diabetic foot ulcer
2011-000090-32Phase 2Unknown
- Sponsor
- BridgeBio Pharma
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic foot ulcer (DFU) comparing BBR-012 + standard medical care with Placebo + standard medical care (2 arms). Primary endpoint: Rate of healing after 28 days. Status: unknown.
02
Drugs
isoniazid
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on 2011-000090-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000090-32.